At the Hart of Pathology
Sitting Down With... John Hart, Professor and Vice Chair of Anatomic Pathology at the University of Chicago Medicine
-
By
-
Helen Bristow
-
April 27, 2026
-
Clinical Scorecard: At the Hart of Pathology
At a Glance
| Category | Detail |
|---|
| Condition | Hepatitis C and drug-induced liver injury |
| Key Mechanisms | Molecular techniques including next-generation sequencing (NGS) and HLA typing |
| Target Population | Patients with liver diseases and those at risk for drug-induced liver injury |
| Care Setting | Pathology laboratories and academic medical centers |
Key Highlights
- Hepatitis C has transitioned from a prevalent condition to one that is largely eradicated due to advancements in treatment.
- Molecular pathology is transforming the diagnosis of liver diseases and inflammatory GI conditions.
- Next-generation sequencing (NGS) has revealed genetic susceptibility to drug reactions.
- HLA typing helps identify patients at risk for adverse reactions to drugs and herbal supplements.
- The fellowship program fosters the next generation of leaders in GI and liver pathology.
Guideline-Based Recommendations
Diagnosis
- Utilize molecular techniques for the diagnosis of liver diseases.
Management
- Counsel patients on drug and supplement avoidance based on HLA typing results.
Monitoring & Follow-up
- Regularly assess patients for liver function and potential drug-induced injuries.
Risks
- Identify genetic predispositions to drug reactions to mitigate risks.
Patient & Prescribing Data
Individuals with liver diseases and those on medications with known hepatotoxic potential.
Understanding genetic factors can guide safer prescribing practices.
Clinical Best Practices
- Incorporate molecular pathology techniques into routine diagnostics.
- Engage in continuous education and training for fellows and residents.
- Foster collaboration and knowledge exchange within the pathology community.
References
